Mylan Labs Loses License for Alprazolam Diversion
By Rediff Money Desk, HYDERABAD Feb 14, 2024 18:28
Mylan Laboratories Ltd's product manufacturing licence for Alprazolam has been cancelled after an unauthorized diversion of the psychotropic drug was detected in Telangana. The drug is used for anxiety disorders but can be addictive.
Hyderabad, Feb 14 (PTI) The Telangana Drugs Control Administration on Wednesday said it has cancelled the product manufacturing licence of Mylan Laboratories Ltd for the drug Alprazolam' after an allegedly unauthorized diversion of the psychotropic drug was detected from its unit in the state.
The unauthorised diversion, which could potentially lead to abuse of the addictive drug Alprazolam', came to the notice of the Drugs Control Administration, Telangana, from Excise authorities, DCA Director General V B Kamalasan Reddy said in a release.
The Telangana Drugs Control Administration (DCA) said that Prohibition and Excise authorities had found that 21.250 kilogram of Alprazolam was diverted, unauthorized, from the licensed premises of Mylan Laboratories Ltd Unit-7, at Sangareddy District, through certain employees who were working as chemists and production officers.
In a related incident, 4.850 kilogram of Alprazolam had been seized in February last year by Prohibition and Excise authorities from the consumables room of Mylan Laboratories Ltd Unit-7, they said.
DCA Telangana issued a show cause notice to Mylan Laboratories Ltd, upon carrying out an inspection of the site, as the firm failed to notify the Telangana DCA of the alleged unauthorized diversion of Alprazolam from its licensed premises.
The notice was issued also over certain violations reported by DCA officers regarding the lack of adequate controls for the prevention and detection of such unauthorised diversion, an official said.
Considering the nature of the violations reported regarding the drug Alprazolam', which is a psychotropic substance, and its unauthorised diversion from Mylan Laboratories Ltd., Unit-7, upon assessment of the existing controls and practices at the site, the manufacturing licence for the drug Alprazolam' has been cancelled by the Drugs Control Administration, Telangana, with immediate effect, in the larger public interest, the DCA Director General said.
The licence held Mylan Laboratories Ltd Unit-7, Pashamylaram, Patancheru Mandal, Sangareddy District had been for the manufacture of the drug Alprazolam' (Active Pharmaceutical Ingredient).
The licence issued by the Telangana DCA had included permission for the activities of manufacturing the bulk drug Alprazolam (API) and supplying the drug exclusively to the formulation (tablets/injections) manufacturing units, the release said.
Alprazolam' is a psychotropic substance under Narcotic Drugs and Psychotropic Substances Act (NDPS Act) and is used as a medicine to treat anxiety disorders, panic disorders, anxiety associated with depression, insomnia. The addiction/habit-forming potential of Alprazolam is very high.
The abuse of Alprazolam can lead to various adverse effects including addiction, physical dependence, and withdrawal symptoms upon discontinuation, the release added.
The unauthorised diversion, which could potentially lead to abuse of the addictive drug Alprazolam', came to the notice of the Drugs Control Administration, Telangana, from Excise authorities, DCA Director General V B Kamalasan Reddy said in a release.
The Telangana Drugs Control Administration (DCA) said that Prohibition and Excise authorities had found that 21.250 kilogram of Alprazolam was diverted, unauthorized, from the licensed premises of Mylan Laboratories Ltd Unit-7, at Sangareddy District, through certain employees who were working as chemists and production officers.
In a related incident, 4.850 kilogram of Alprazolam had been seized in February last year by Prohibition and Excise authorities from the consumables room of Mylan Laboratories Ltd Unit-7, they said.
DCA Telangana issued a show cause notice to Mylan Laboratories Ltd, upon carrying out an inspection of the site, as the firm failed to notify the Telangana DCA of the alleged unauthorized diversion of Alprazolam from its licensed premises.
The notice was issued also over certain violations reported by DCA officers regarding the lack of adequate controls for the prevention and detection of such unauthorised diversion, an official said.
Considering the nature of the violations reported regarding the drug Alprazolam', which is a psychotropic substance, and its unauthorised diversion from Mylan Laboratories Ltd., Unit-7, upon assessment of the existing controls and practices at the site, the manufacturing licence for the drug Alprazolam' has been cancelled by the Drugs Control Administration, Telangana, with immediate effect, in the larger public interest, the DCA Director General said.
The licence held Mylan Laboratories Ltd Unit-7, Pashamylaram, Patancheru Mandal, Sangareddy District had been for the manufacture of the drug Alprazolam' (Active Pharmaceutical Ingredient).
The licence issued by the Telangana DCA had included permission for the activities of manufacturing the bulk drug Alprazolam (API) and supplying the drug exclusively to the formulation (tablets/injections) manufacturing units, the release said.
Alprazolam' is a psychotropic substance under Narcotic Drugs and Psychotropic Substances Act (NDPS Act) and is used as a medicine to treat anxiety disorders, panic disorders, anxiety associated with depression, insomnia. The addiction/habit-forming potential of Alprazolam is very high.
The abuse of Alprazolam can lead to various adverse effects including addiction, physical dependence, and withdrawal symptoms upon discontinuation, the release added.
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Srestha Finvest
- 0.66 ( -4.35)
- 63189095
- Srestha Finvest
- 0.66 ( -4.35)
- 63189095
- Vodafone Idea L
- 8.05 ( -1.59)
- 33337300
- Vodafone Idea L
- 8.05 ( -1.59)
- 33337300
- Rajnish Wellness
- 2.03 ( -4.69)
- 17037456
MORE NEWS
CCI Proposes Penalty Recovery Changes: Public...
CCI proposes amendments to its penalty recovery process under the Competition Act,...
Jagran Prakashan Q2 Profit Up, Revenue Down - PTI
Jagran Prakashan Ltd, publisher of Dainik Jagran, reported a slight rise in Q2 net...
Ratan Tata Honored by Deutsche Bank: Business News
Deutsche Bank honors Ratan Tata's legacy with a commemorative plaque in Mumbai. Also,...